19 May 2026

Coiled Therapeutics plc

("Coiled Therapeutics" or the "Company")

Commencement of Trading on US OTCQB Venture Market

Coiled Therapeutics (AIM:COIL), the clinical-stage oncology company developing precision medicines for hard-to-treat cancers, announces that trading in the Company's ordinary shares of one pence each ("Ordinary Shares") will commence today on the OTCQB Venture Market in the United States. The Company's OTCQB shares have the ticker: COTXF

Coiled Therapeutics' Ordinary Shares will continue to trade on the AIM Market of the London Stock Exchange, under the ticker COIL.

Cross trading on the OTCQB market allows the Company to access one of the world's largest investment markets to expand its reach into a broader pool of investors. Coiled Therapeutics shares will be available to US investors during US working hours and priced in US dollars and thus has the potential to enable greater liquidity in the Company's shares on the London Stock Exchange by easing cross-border trading for potential US investors. Further information about the OTCQB market can be found at: www.otcmarkets.com/learn/market-101

As a Foreign Private Issuer, Coiled Therapeutics' onboarding to the OTC Markets is based on satisfaction of the requirements for OTCQB as applicable to international reporting companies including satisfaction of the criteria for the exemption under the US Exchange Act Rule 12g3-2(b) from SEC reporting. The Rule 12g3-2(b) exemption includes the disclosure obligation to ensure that certain information made public or distributed under home market regulations is made publicly available on the Company's website or other electronic information delivery system in English. Thus, the Company will have no additional reporting obligations and incur minimal ongoing costs, compared to traditional major exchanges.

As a verified market, the OTCQB offers transparent trading for companies that have met a minimum bid price test, are current in their financial reporting and have undergone an annual verification and management certification process. The cross-trading facility is provided through OTC Markets Group Inc., located in New York. OTC Markets operates the world's largest electronic interdealer quotation system for US broker dealers and offers multiple media channels to increase the visibility of OTC-listed companies. Online brokers such as Fidelity, TradeStation, Charles Schwab, Interactive Brokers and E-trade all offer trading of OTCQB shares. US investors can find real-time quotes, market information and access current company news and developments for Coiled Therapeutics at https://www.otcmarkets.com/stock/COTXF/overview.

Sridhar Vempati, Chief Executive Officer of Coiled Therapeutics, commented:

"We are pleased to commence trading on the OTCQB Venture Market, which we believe complements our AIM listing well by opening up Coiled Therapeutics to a broader pool of US-based investors and the potential for enhanced liquidity in our shares. This is an exciting time for the Company, following the highly encouraging clinical data from Cohort 4b in our ongoing clinical trial, which delivered an 80% Clinical Benefit Rate and durable responses in a heavily pre-treated patient population. With dose escalation on track for completion in H1 2026 and multiple data catalysts ahead, we believe 2026 will be a transformational year for Coiled Therapeutics, and we look forward to welcoming new US investors as we deliver on our clinical and strategic milestones."

Enquiries:

About Coiled Therapeutics plc

Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884).  Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments.   The Company is also assessing its STAT-6 siRNA programme for immunology indications. Coiled Therapeutics is supported by a leadership team with a proven track record in drug development and strategic backing from A2A Pharmaceuticals.

About AO-252

AO-252 is a first-in-class, orally administered, brain-penetrant small molecule inhibitor of Transforming Acidic Coiled-Coil containing protein 3 (TACC3). TACC3 is a validated oncology target that is frequently overexpressed in many aggressive, hard-to-treat solid tumours but is dispensable in normal adult cells, providing a wide therapeutic window.

By selectively disrupting cancer-critical protein-protein interactions at the TACC3 C-terminal domain, AO-252 induces mitotic and replication stress, impairs DNA damage repair, and triggers cancer cell death. Notably, AO-252 has demonstrated the ability to cross the blood-brain barrier, addressing a significant unmet medical need for the treatment of brain metastases.

The asset is currently in an ongoing Phase I open-label dose-escalation study and early clinical signals have shown encouraging anti-tumour activity and a benign safety profile, with the Company planning to initiate dose expansion cohorts in lead indications, including prostate and ovarian cancer, during 2026.

For more information, please visit: www.coiledplc.com